Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 27;72(S3):S193-S207.
doi: 10.33549/physiolres.935153.

Circulating exosomal miRNAs as a promising diagnostic biomarker in cancer

Affiliations
Review

Circulating exosomal miRNAs as a promising diagnostic biomarker in cancer

R Lohajová Behulová et al. Physiol Res. .

Abstract

Cancer belongs to multifactorial diseases characterized by uncontrolled growth and proliferation of abnormal cells. Breast cancer, non-small cell lung cancer, and colorectal cancer are the most frequently diagnosed malignancies with a high mortality rate. These carcinomas typically contain multiple genetically distinct subpopulations of tumor cells leading to tumor heterogeneity, which promotes the aggressiveness of the disease. Early diagnosis is necessary to increase patient progression-free survival. Particularly, miRNAs present in exosomes derived from tumors represent potential biomarkers suitable for early cancer diagnosis. Identification of miRNAs by liquid biopsy enables a personalized approach with the subsequent better clinical management of patients. This review article highlights the potential of circulating exosomal miRNAs in early breast, non-small cell lung, and colorectal cancer diagnosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

There is no conflict of interest.

Figures

Fig. 1
Fig. 1
Different functions of miRNAs in oncogenesis

Similar articles

Cited by

References

    1. Cancer Burden Statistics and Trends Across Europe. 2020. p. ECIS. https://ecis.jrc.ec.europa.eu/
    1. Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends in Cancer. 2020;6:580–592. doi: 10.1016/j.trecan.2020.02.003. - DOI - PMC - PubMed
    1. Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. Precis Oncol. 2019;3:1–8. doi: 10.1038/s41698-019-0079-0. - DOI - PMC - PubMed
    1. Eu Commision. Council conclusions on personalised medicine for patients. Off J Eur Union. 2015;58:1–32.
    1. Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Personalized medicine: recent progress in cancer therapy. cancers (Basel) 2020;12:1009. doi: 10.3390/cancers12041009. - DOI - PMC - PubMed

MeSH terms